Icotrokinra
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Icotrokinra
- Structure (SMILES)
- c1c2ccccc2ccc1C[C@H](NC(=O)[C@@H](NC(=O)[C@H]3NC([C@H](CCCCNC(=O)C)NC(=O)[C@H](Cc4c5c(c(ccc5)C)[nH]c4)NC([C@@](NC(=O)[C@@H](NC(=O)[C@H](C(C)(SSC3(C)C)C)NC(=O)C)CC(=O)N)([C@@H](C)O)[H])=O)=O)Cc6ccc(OCCN)cc6)C(=O)NC7(C(=O)N[C@H](C(N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc8cnccc8)C(N(CC(=O)N)C)=O)=O)CCC(O)=O)CCOCC7
- icotrokinra
- Icotrokinra
- icotrokinra [INN]
- ICOTROKINRA [USAN]
- Icotrokinra [WHO-DD]
- icotrokinra inn
- icotrokinra usan
- icotrokinra who dd
- jnj 77242113
- jnj 77242113 aac free base
- JNJ-77242113
- JNJ-77242113-AAC FREE BASE
- CAS registry numbers
- 2763602-16-8
- ChEMBL ID
- CHEMBL6068124
- InChIKey
- IVFNYXYPMJQSGF-QMRCQSNESA-N
- PubChem compound IDs
- 162462321
- RxNorm IDs (RxCUI)
- 2739030
- FDA ingredient codes (UNII)
- MUW8FP7HNZ
- Patents
- 3
- Designations
- 0
- Earliest recorded loss of exclusivity
- 19 Nov 2041
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- icotrokinra
- Type
- Peptide
- Drug name stem
- -kinra
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Interleukin-23 receptor
- Gene symbol
- IL12RB1
- Protein identifier
- P42701
- Median affinity
- 11.33
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Interleukin-23 receptor
- Gene symbol
- IL12RB1
- Protein identifier
- P42701
- Median affinity
- 11.7
- Affinity units
- pKd
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Interleukin-23 receptor
- Gene symbol
- IL23R
- Protein identifier
- Q5VWK5
- Median affinity
- 11.33
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Interleukin-23 receptor
- Gene symbol
- IL23R
- Protein identifier
- Q5VWK5
- Median affinity
- 11.7
- Affinity units
- pKd
- Primary target
- Yes
- Condition identifier
- EFO_0000384
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003778
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011849
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100491
- Highest recorded phase
- 3
- Calculated partition coefficient (XLogP)
- -3.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 134
- Monoisotopic mass
- 1896.83274788
- Natural product
- No
- 57894-201
Related records
Trials (16)
- A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants
- A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
- A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
- A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
- A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants
- A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
- A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
In development for (2)
- Psoriatic arthritis Phase 3
- Ulcerative colitis Phase 3